gene

APP

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about APP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

6264Connections
13Hypotheses
25Analyses
50Outgoing
50Incoming
3Experiments
20Debates

Summary

Amyloid Precursor Protein (APP) is a type I transmembrane protein critical for neuronal development, synapse formation, and iron homeostasis. APP is cleaved by two competing pathways: the non-amyloidogenic pathway (alpha-secretase ADAM10) producing neuroprotective sAPPalpha, and the amyloidogenic pathway (BACE1 and gamma-secretase) producing amyloid-beta peptides (Abeta40 and Abeta42). Accumulation of Abeta42 triggers the amyloid cascade hypothesis of Alzheimer's disease. Over 50 familial AD mutations in APP increase Abeta42 production or aggregation propensity. APP is located on chromosome 21, explaining early-onset AD in Down syndrome. Current therapies target APP processing (BACE1 inhibitors, gamma-secretase modulators) or Abeta clearance (anti-amyloid antibodies like lecanemab and donanemab).

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolAPP
Full NameAmyloid Precursor Protein
Chromosome21q21.3
Protein TypeProtein
Functionis a type I transmembrane glycoprotein that plays a central role in the pathogenesis of Alzheimer's disease (AD).
Primary ExpressionUbiquitous, highest in brain
Molecular Weight~110 kDa
Exons18
PathwaysAmyloid, Angiogenesis, Apoptosis, Autophagy, Blood-Brain Barrier
UniProt IDP05067
NCBI Gene ID351
Ensembl IDENSG00000142192
OMIM104760
GeneCardsAPP
Human Protein AtlasAPP
Associated DiseasesAD, aging, Als, Alzheimer
Known Drugs/CompoundsAbeta, aducanumab, Atractylodes macrocephala, berberine, BERBERINE, D-520
InteractionsA2M, ABCA1, ABCA7, ACETYLCHOLINE, ACHE, ACSL4
SciDEX HypothesesSelective Cholinergic Protection via APP Pathway M
Amyloid Precursor Protein Processing Modulation vi
KG Connections4396 knowledge graph edges
DatabasesGeneCardsHPASTRING
🧬 3D Structure Comparison — APP Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

1AAP — X-ray / Cryo-EM

🔮 AI Predicted Structure

P05067 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

APP Protein

protein · 4363 words

APP Flemish Mutation (APP Flemish)

disease · 3868 words

Amyloid Precursor Protein (APP)

entity · 3485 words

APP→Amyloid-beta→Plaque→Alzheimer's Disease Causal Chain

pathway · 3076 words

APP — Amyloid Precursor Protein

gene · 2551 words

APP-BACE1-Fe65 Complex

mechanism · 2240 words

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        APP["APP"] -->|"associated with"| Cancer["Cancer"]
        APP["APP"] -->|"associated with"| Neurodegeneration["Neurodegeneration"]
        APP["APP"] -->|"associated with"| PSEN1["PSEN1"]
        APP["APP"] -->|"associated with"| Alzheimer_3["Alzheimer"]
        APP["APP"] -->|"associated with"| Als_4["Als"]
        APOE["APOE"] -->|"associated with"| APP["APP"]
        APOPTOSIS["APOPTOSIS"] -->|"associated with"| APP["APP"]
        ALZHEIMER_S_DISEASE_5["ALZHEIMER'S DISEASE"] -->|"associated with"| APP["APP"]
    end
    subgraph Signaling["Signaling"]
        APP["APP"] -->|"activates"| Alzheimer["Alzheimer"]
        APP["APP"] -->|"activates"| Als_2["Als"]
        APP_PS1["APP/PS1"] -.->|"inhibits"| APP["APP"]
        APP_PS1_6["APP/PS1"] -->|"activates"| APP["APP"]
    end
    subgraph Therapeutic["Therapeutic"]
        APP["APP"] -->|"therapeutic target"| Alzheimer_1["Alzheimer"]
        APP["APP"] -->|"therapeutic target"| Als["Als"]
        ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"therapeutic target"| APP["APP"]
    end
    style APP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style Cancer fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer_1 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_2 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style PSEN1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer_3 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_4 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APOE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APP_PS1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APOPTOSIS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE_5 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APP_PS1_6 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (3300)

TargetRelationTypeStr
ad_genetic_risk_loci:APPdata_indataset_row0.00
benchmark_ot_ad_answer_key:APPdata_indataset_row0.00
ASTROCYTESassociated_withcell_type1.00
Dementiaactivatesdisease1.00
CORTEXassociated_withbrain_region1.00

Incoming (2964)

SourceRelationTypeStr
entities-norepinephrineassociated_withwiki0.00
benchmark_ot_ad_answer_key:APPdata_indataset_row0.00
ad_genetic_risk_loci:APPdata_indataset_row0.00
benchmark_ot_ad_answer_key:APPdata_indataset_row0.00
ad_genetic_risk_loci:APPdata_indataset_row0.00

Targeting Hypotheses (13)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Endosomal trafficking defects are the common upstream lesion 0.730 neurodegeneration What determines the temporal sequence of
Selective Cholinergic Protection via APP Pathway Modulation 0.629 neurodegeneration Clinical Trial Landscaping for Alzheimer
Locus coeruleus degeneration gates whether cholinergic dysfu 0.620 neurodegeneration What determines the temporal sequence of
Glycosaminoglycan Template Disruption Approach 0.597 neurodegeneration Protein aggregation cross-seeding across
Synthetic Biology Approach: Designer Mitochondrial Export Sy 0.505 neurodegeneration Mitochondrial transfer between neurons a
CX3CR1 PET with Nano-bodies for Microglial Surveillance Stat 0.477 biomarkers What biomarkers can reliably detect micr
Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic 0.470 neurodegeneration Why do structurally diverse sugars (treh
Cdk5/p25-PSD-95 Phosphorylation Disrupts Synaptic Scaffoldin 0.455 neurodegeneration Quantitative proteomics of the aging syn
Synaptic Vesicle Protein Phosphorylation Reprograms Release 0.455 neurodegeneration Quantitative proteomics of the aging syn
AD fine-mapping identifies causal variants in microglia-spec 0.380 alzheimers Statistical Fine-Mapping of AD GWAS Loci
APP Processing Compartmentalization Therapeutics 0.000 - Lipid raft composition changes in synapt
Amyloid Precursor Protein Processing Modulation via Bacteria 0.000 - Gut-Brain Axis Therapeutics for Alzheime
Novel CRISPR-based Therapies for Huntington's Disease: A Mul 0.000 neurodegeneration -

Mentioning Analyses (25)

Scientific analyses that reference this entity

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

neurodegeneration | 2026-04-25 | 6 hypotheses Top: 0.387

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

Lipid metabolism dysregulation in Alzheimer's disease: membrane rafts, gangliosi

lipidomics | 2026-04-16 | 13 hypotheses Top: 0.802

Quantitative proteomics of the aging synapse: protein turnover and aggregation i

proteomics | 2026-04-16 | 19 hypotheses Top: 0.591

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.734

Experiments (3)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Plasma ATN biomarkers across AD continuum in Chilean cohort clinical Alzheimer's disease 0.950 0.00 Chilean older adults (n=318) w proposed N/A
Adoptive transfer of TCRAβ-Tregs in AD mouse model validation Alzheimer's disease 0.900 0.00 transgenic mice expressing chi proposed N/A
E2F coordination of G2/M transcriptional program exploratory 0.750 0.00 endocycling mammalian cells proposed N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Enhancing the efficiency of bone tissue regeneration by using a 3D printed scaff [PMID:41435437] Ku CY, Chen YH, Lin CM, Chu YH, Ho YJ, L Biomedical materials (Bristol, 2026 0
Cataract Aggravates Alzheimer-Like Pathologies and Cognitive Deficits in an APP/ [PMID:40580389] Geng Z, Yu ZY, Tan J, Wang XY, Zeng GH e Neurosci Bull 2026 0
Integrating biocatalysis with continuous flow: current status, challenges, and f [PMID:40639553] Bai J, Huang C, Liu Y, Zheng X, Liu J et J Adv Res 2026 0
Engineering chimeric signaling proteins for microbial whole-cell biosensors: fro [PMID:40903364] Özer Bergman G, Mecacci S, Martins Dos S Trends Biotechnol 2026 0
MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario. [PMID:41512197] Rodon J, Johnson ML, George B, Shah PA, Cancer Res 2026 0
HOPS disruption impairs APP trafficking and processing, promoting exosomal secre [PMID:41525887] Draper D, George AE, Veenendaal T, van D Neurobiol Dis 2026 0
TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] Feiten AF, Dahm K, Schlepckow K, van Len Nat Commun 2026 0
APP-C31 pathology as a target in neurodegenerative diseases. [PMID:41639863] Yip KC, Ho WF, Liu Y, Dawe GS J Biomed Sci 2026 0
Decoding Alzheimer's disease through down syndrome: insights from a genetically [PMID:41709686] Russell JK, Schlachetzki Z, Rafii MS Curr Opin Neurol 2026 0
Apps for people with vision impairment: an international review of practitioner [PMID:41734772] Gothwal VK, Miller A, Boon MY, Subramani Clin Exp Optom 2026 0
Impaired TGFβ Signaling in Plaque-Associated Microglia. [PMID:41750318] Krzyzan O, Kuhla A, Spittau B, Vidovic N Biomolecules 2026 0
Design and synthesis of BAP-1 inhibitors. [PMID:41761813] Zhang Z, Yang X Pak J Pharm Sci 2026 0
Optimized bacterial expression of a synthetic BRIL antibody. [PMID:41842660] Cooper BF, Isom GL Acta Crystallogr F Struct Biol 2026 0
APP as an innate injury-response molecule. [PMID:41864298] Olmsted ZT, Sofroniew MV Neurobiol Dis 2026 0
CRISPR-Cas9 and next-generation gene editing strategies for therapeutic interven [PMID:41931258] Khan MS, Zafar I, Jamal A, Bahwerth FS, Acta Neurol Belg 2026 0
Akkermansia muciniphila reduces neuroinflammation and Aβ deposition via tryptoph [PMID:41715194] Wang B, Pan M, Yang L, Xu J, Ye C, Li Y, Alzheimer's research & therapy 2026 0
Alzheimer's disease basics: we all should know. [PMID:40639927] Das S Neurological research 2026 0
Cerebral FURIN deficiency impairs astrocytic lipophagy through ITGAV maturation. [PMID:41376284] Xie XY, Wang L, Xie SQ, Zhou GF, Wen QX, Autophagy 2026 0
Bacterial DNA methylases as novel molecular and synthetic biology tools: recent [PMID:40047928] Flores-Fernández CN, O'Callaghan CA Applied microbiology and biote 2025 0
Trichomonas vaginalis adhesion protein 65 facilitates human papillomavirus entry [PMID:41199321] Mei X, Sheng W, Zhang Y, Tian W, Tian X, Infectious diseases of poverty 2025 0

Debates (20)

Multi-agent debates referencing this entity

Second debate: Microglial TREM2-SYK Pathway Enhancement

closed · Rounds: 4 · Score: 0.57 · 2026-04-28

Structured research brief (iter2): ω-3 Docosahexaenoic Acid (DHA) Epoxide Genera

archived · Rounds: 2 · Score: 0.64 · 2026-04-28

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Extended debate: Closed-loop transcranial focused ultrasound with 40Hz gamma ent

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Extended debate: Closed-loop tACS targeting EC-II SST interneurons to block tau

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Debate: Closed-loop transcranial focused ultrasound targeting entorhinal PV inte

closed · Rounds: 4 · Score: 0.65 · 2026-04-27

Debate: Chromatin Remodeling-Mediated Nutrient Sensing Restoration

closed · Rounds: 4 · Score: 0.46 · 2026-04-27

Debate: Closed-loop tACS targeting EC-II SST interneurons to block tau propagati

closed · Rounds: 4 · Score: 0.71 · 2026-04-27

Debate: Closed-loop transcranial focused ultrasound to restore hippocampal gamma

closed · Rounds: 4 · Score: 0.87 · 2026-04-27

Debate: Closed-loop tACS targeting EC-II PV interneurons to suppress burst firin

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Related Research

Hypotheses and analyses mentioning APP in their description or question text

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Score: 0.477 · biomarkers · 2026-04-22

## Mechanistic Overview CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping starts from the claim that

Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic Trapping)

Score: 0.470 · neurodegeneration · 2026-04-21

## Mechanistic Overview Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic Trapping) starts from the claim that

Cdk5/p25-PSD-95 Phosphorylation Disrupts Synaptic Scaffolding and Shifts APP Pro

Score: 0.455 · neurodegeneration · 2026-04-27

Age-dependent p35-to-p25 cleavage activates Cdk5, which phosphorylates PSD-95 S561, disrupting AMPA/NMDA receptor anchor

Synaptic Vesicle Protein Phosphorylation Reprograms Release Probability and Inte

Score: 0.455 · neurodegeneration · 2026-04-27

Synaptic activity-dependent phosphorylation of synapsin-1 by CamKII and calcineurin dynamically regulates vesicle mobili

AD fine-mapping identifies causal variants in microglia-specific enhancers with

Score: 0.380 · alzheimers · 2026-04-26

Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupt

APP Processing Compartmentalization Therapeutics

Score: 0.000 · unknown disease · 2026-04-28

Selective targeting of secretase localization to shift APP processing from amyloidogenic to non-amyloidogenic pathways

Amyloid Precursor Protein Processing Modulation via Bacterial Enzyme Delivery

Score: 0.000 · unknown disease · 2026-04-28

Engineered gut bacteria producing α-secretase-like enzymes or β-secretase inhibitors can be delivered orally to influenc